Drug Sales Trends for fenofibrate

Payment Methods and Pharmacy Types for fenofibrate (2008)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
MAIL-ORDER	$7,855,889
INSIDE ANOTHER STORE	$4,833,548

Units Sold by Pharmacy Type

Pharmacy Type	Units
MAIL-ORDER	112,698
INSIDE ANOTHER STORE	78,543

Revenues by Payment Method

Payment Method	Revenues
MEDICAID	$5,052,055
MEDICARE	$18,372,092

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for fenofibrate

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
FENOFIBRATE			2022
FENOFIBRATE			2021
FENOFIBRATE			2020
FENOFIBRATE			2019
FENOFIBRATE			2018

Fenofibrate Market Analysis, Sales Projections, Patent Expiry, and Generic Competition

Last updated: September 1, 2026

Fenofibrate is a mature, largely generic lipid-lowering drug with stable prescription demand but limited pricing power. The market is driven by chronic treatment of hypertriglyceridemia and mixed dyslipidemia, while competition from statins, prescription omega-3 products, PCSK9 inhibitors, and newer cardiometabolic therapies limits growth. The base-case outlook is declining low-single-digit annual sales through 2029 as generic prices fall and branded volume continues to migrate to low-cost suppliers.

What is the current market position of fenofibrate?

Fenofibrate is a peroxisome proliferator-activated receptor alpha, or PPAR-alpha, agonist. It lowers triglycerides and can increase high-density lipoprotein cholesterol. The drug is available in multiple oral formulations, including capsules and tablets, with several strengths and release technologies.

The leading historical brands include:

• Tricor, marketed by Abbott and later AbbVie
• Trilipix, a fenofibric acid product associated with Abbott
• Antara
• Lipofen
• Triglide
• Generic fenofibrate tablets and capsules

The commercial market is now dominated by generic fenofibrate. Brand products retain limited value in some channels through legacy prescribing, payer formulary positioning, or manufacturer contracting.

Fenofibrate demand remains linked to:

1. Severe hypertriglyceridemia and pancreatitis-risk management.
2. Mixed dyslipidemia when triglycerides remain elevated.
3. Patients who are intolerant of, or inadequately controlled by, statin therapy.
4. Combination treatment with statins in selected patients.

The American College of Cardiology and American Heart Association treatment framework places statins and lifestyle intervention at the center of atherosclerotic cardiovascular disease risk reduction. Fenofibrate is used more selectively, particularly when triglycerides are substantially elevated. The FDA label states that fenofibrate has not been shown to reduce coronary heart disease morbidity and mortality in large clinical outcomes studies [1].

How large is the fenofibrate market?

No single public source reports consolidated global revenue for all fenofibrate formulations, manufacturers, countries, hospital channels, and private-label suppliers. A practical market estimate therefore requires a prescription-volume and net-price model.

Modeled 2024 market range

Market	Estimated annual prescriptions or treatment equivalents	Modeled net revenue
United States	20 million to 28 million 30-day equivalents	$180 million to $420 million
Europe	20 million to 35 million treatment equivalents	$180 million to $400 million
Japan and other developed markets	15 million to 25 million treatment equivalents	$150 million to $350 million
Emerging markets	35 million to 70 million treatment equivalents	$250 million to $600 million
Global total	90 million to 158 million treatment equivalents	$760 million to $1.77 billion

These values are analytical market ranges rather than reported manufacturer revenue. The broad range reflects differences in generic pricing, tender procurement, reimbursement systems, dose strength, formulation, and whether sales are measured at manufacturer, wholesaler, pharmacy, or patient-pay level.

The United States has substantial prescription volume but relatively low generic prices. Emerging markets can generate higher unit volume but lower average selling prices. Branded fenofibrate contributes only a small portion of global molecule sales.

What are the fenofibrate sales projections through 2029?

The base case assumes declining US and European prices, stable-to-slightly declining treatment volume, modest growth in emerging markets, and continued substitution toward low-cost generic suppliers.

Global fenofibrate sales projection

Year	Bear case	Base case	Bull case
2024	$760 million	$1.10 billion	$1.77 billion
2025	$710 million	$1.06 billion	$1.79 billion
2026	$660 million	$1.02 billion	$1.80 billion
2027	$610 million	$990 million	$1.82 billion
2028	$565 million	$960 million	$1.84 billion
2029	$525 million	$930 million	$1.86 billion
2024-2029 CAGR	-6.9%	-3.3%	1.0%

The base case implies that global fenofibrate sales decline by about 15% from 2024 to 2029. The decline is mainly a price effect. Prescription demand should remain comparatively resilient because hypertriglyceridemia is chronic and fenofibrate remains inexpensive.

United States sales projection

Year	Base-case US market
2024	$300 million
2025	$292 million
2026	$283 million
2027	$275 million
2028	$267 million
2029	$259 million

The US base case assumes a prescription volume decline of approximately 0.5% to 1.5% annually and a net-price decline of approximately 2% to 4% annually. A faster decline would occur if additional manufacturers enter low-volume dosage forms or if payers consolidate purchasing through larger generic contracts.

Which factors will drive fenofibrate demand?

Persistent use in severe hypertriglyceridemia

Fenofibrate retains a clear clinical role in patients with very high triglycerides, particularly when the treatment objective includes reducing pancreatitis risk. This population is smaller than the broader statin market but creates recurring demand.

Generic affordability

Low price supports continued use in primary care and endocrinology. Fenofibrate is substantially less expensive than PCSK9 antibodies and many newer lipid-lowering therapies. That cost advantage supports demand in markets with strict reimbursement controls.

Combination use with statins

Fenofibrate may be used alongside statins in selected patients with high triglycerides and low HDL cholesterol. The overall cardiovascular benefit of routine combination therapy is limited. In the ACCORD Lipid trial, fenofibrate added to simvastatin did not significantly reduce major cardiovascular events in the overall study population [2].

Diabetes and metabolic disease prevalence

Type 2 diabetes, obesity, metabolic syndrome, and chronic kidney disease are associated with abnormal triglyceride profiles. Growth in these conditions supports the underlying patient pool. The commercial impact is moderated by increasing use of statins and newer diabetes medicines that may improve lipid profiles indirectly.

Clinical guideline selectivity

Guidelines generally prioritize lifestyle intervention, statins, and prescription omega-3 therapy when clinically appropriate. Fenofibrate use is therefore concentrated in defined subgroups rather than broad preventive prescribing [3].

How does fenofibrate compare with competing lipid-lowering drugs?

Drug class	Primary lipid effect	Typical market position	Commercial implication for fenofibrate
Statins	LDL cholesterol reduction	First-line therapy	Limits fenofibrate use in routine dyslipidemia
Fenofibrate	Triglyceride reduction, HDL increase	Severe triglycerides and mixed dyslipidemia	Retains low-cost niche
Icosapent ethyl	Triglyceride reduction and cardiovascular risk reduction in selected patients	Premium adjunct therapy	Competes for high-risk patients
Other prescription omega-3 products	Triglyceride reduction	Severe hypertriglyceridemia	Competes where triglyceride lowering is the priority
PCSK9 inhibitors	Large LDL reduction	High-risk or familial hypercholesterolemia	Limited direct overlap, but captures intensive lipid-management budgets
Bempedoic acid	LDL reduction	Statin-intolerant patients	Expands alternatives for LDL management
Ezetimibe	LDL reduction	Low-cost add-on therapy	Competes when LDL, rather than triglycerides, is the treatment target

Fenofibrate is unlikely to displace statins or PCSK9 therapies. Its strongest commercial position is as a low-cost triglyceride-lowering option where LDL cholesterol is not the primary unresolved risk.

What patents protect fenofibrate products?

The core fenofibrate compound is an old small molecule, and its foundational patent protection has expired. The original commercial opportunity depended on formulation, dosage, bioavailability, and salt or ester technologies rather than ongoing compound exclusivity.

Historical formulation and product protection

Product or technology	Protection type	Current commercial significance
Tricor	Formulation and bioavailability claims	Historical protection; generic competition established
Triglide	Formulation and particle-size technology	Historical protection; no meaningful compound exclusivity
Antara	Micronized or modified formulation	Historical product differentiation
Lipofen	Formulation and release characteristics	Historical protection
Trilipix	Fenofibric acid active moiety and formulation	Separate product lineage from standard fenofibrate

Fenofibrate formulation patents historically addressed micronization, dissolution, particle size, food-effect reduction, and delivery of poorly water-soluble drug material. These patents delayed generic substitution for some products but did not create durable protection after the main patents expired.

When does fenofibrate lose exclusivity?

Fenofibrate has already lost primary market exclusivity in the United States and major international markets. The molecule is not protected by an active new chemical entity exclusivity period.

Relevant FDA milestones include:

• Original fenofibrate products were approved decades ago.
• Generic versions were approved through the abbreviated new drug application pathway.
• Multiple dosage forms and strengths are listed in FDA product and Orange Book records.
• Brand-specific formulation patents have expired or no longer prevent broad generic substitution.

Because fenofibrate is a generic small molecule, biosimilar risk does not apply. The relevant competitive threat is ANDA-based generic entry, formulation substitution, private-label supply, and price competition.

What is the Orange Book status of fenofibrate?

The FDA Orange Book lists approved prescription drug products, therapeutic equivalence information, and patent or exclusivity information where applicable [4]. Fenofibrate products are generally classified as mature generic products with multiple approved suppliers.

Commercial diligence should distinguish among:

• Fenofibrate tablets.
• Fenofibrate capsules.
• Micronized fenofibrate formulations.
• Fenofibric acid products.
• Immediate-release and modified-release products.
• Different strengths that may not have identical substitution patterns.

A generic supplier can have an approved product without achieving automatic substitution across every branded formulation. Therapeutic equivalence depends on the specific reference-listed drug, dosage form, strength, and FDA rating.

Are Paragraph IV challenges still relevant to fenofibrate?

Paragraph IV challenges were commercially important when branded fenofibrate formulations still had active Orange Book patents. The main litigation opportunity involved asserting that listed formulation patents were invalid, unenforceable, or not infringed.

For the current market, Paragraph IV risk is less important than:

• Approval of additional ANDAs.
• Competition among established generic suppliers.
• Active pharmaceutical ingredient sourcing.
• Manufacturing reliability.
• Wholesale contracting.
• State substitution rules.
• Product-specific therapeutic-equivalence ratings.

Any new litigation would likely involve a specific formulation, dosage strength, manufacturing process, or newly developed delivery system rather than the basic fenofibrate molecule.

What generic entry risks exist for fenofibrate manufacturers?

Generic entry risk is high because the active ingredient is mature and multiple suppliers can manufacture it. The main risks are commercial rather than patent-based.

Price erosion

Generic competition can reduce prices rapidly when several suppliers enter the same strength and dosage form. The largest price declines generally occur in products with:

• High prescription volume.
• Simple manufacturing requirements.
• Multiple API suppliers.
• Limited differentiation.
• Broad pharmacy substitution.

Customer concentration

Large wholesalers, pharmacy benefit managers, government programs, and hospital purchasing groups can pressure suppliers for lower prices. A manufacturer with a small portfolio may face significant revenue volatility if it loses one contract.

API and supply-chain risk

Fenofibrate is a synthetic small molecule, and manufacturing barriers are lower than those for complex biologics. Supply risk is more likely to arise from:

• API plant inspections.
• Quality-control findings.
• Single-site dependence.
• Solvent or raw-material disruptions.
• Capacity reallocation by contract manufacturers.

Dosage-form fragmentation

The market is divided across strengths and formulations. A manufacturer with only one capsule strength may not achieve meaningful scale. A broader portfolio can support pharmacy and wholesaler contracting but increases inventory and regulatory complexity.

What formulations are protected by fenofibrate patents?

Historical formulation protection focused on the drug's low aqueous solubility and variable absorption. Key technical approaches included:

• Micronized active pharmaceutical ingredient.
• Nanoparticle or reduced-particle-size material.
• Improved dissolution profiles.
• Reduced dependence on food for absorption.
• Modified-release delivery.
• Tablet and capsule compositions.
• Specific excipient combinations.
• Fenofibric acid formulations.

The most commercially important formulation claims have generally expired or been overtaken by approved generic products. A new entrant would need meaningful differentiation, such as improved adherence, lower dosing frequency, pediatric use, or a clinically validated combination product, to justify new patent expenditure.

What FDA regulatory issues affect fenofibrate sales?

Fenofibrate labeling contains important safety and use limitations. The FDA label identifies risks involving:

• Liver toxicity.
• Renal impairment.
• Gallbladder disease.
• Myopathy and rhabdomyolysis, particularly with statin coadministration.
• Serum creatinine changes.
• Drug interactions, including warfarin and certain statins [1].

Renal dosing is commercially relevant because the target population often includes older adults and patients with chronic kidney disease. Product positioning can be affected by differences in labeling, strength availability, and prescriber familiarity.

Fenofibrate does not have biosimilar competition. It also does not benefit from current biologic exclusivity mechanisms or orphan-drug exclusivity in its principal indications.

Which companies compete in the fenofibrate market?

The market includes branded originators, generic pharmaceutical companies, contract manufacturers, and regional suppliers. Major competitive categories include:

US generic manufacturers

Companies such as Teva, Amneal, Dr. Reddy's, Lupin, Torrent, and other approved ANDA holders have participated in the US generic lipid-lowering market. Supplier participation varies by dosage form and strength.

Branded and specialty suppliers

Historical brand owners include Abbott and AbbVie through the Tricor and related product franchises. Current commercial activity is more fragmented, with limited brand differentiation and generic substitution.

International manufacturers

European, Indian, Chinese, and regional pharmaceutical companies supply fenofibrate products under local brands and tender contracts. The competitive structure varies materially by country because many markets use hospital tenders or national reimbursement pricing.

How strong is the fenofibrate patent estate?

The fenofibrate patent estate is weak from an originator-exclusivity perspective and moderate only for narrowly defined formulation or process claims.

Patent estate dimension	Assessment
Core compound patent	Expired
New chemical entity exclusivity	Expired
Basic oral dosage forms	Broad generic competition
Historical micronization claims	Largely expired or commercially overcome
Specific formulation claims	Potentially relevant only to defined products
Manufacturing-process claims	Limited blocking value unless difficult to design around
Method-of-use claims	Limited value because treatment indications are established
Biosimilar barrier	Not applicable
Generic substitution risk	High
Sustainable pricing power	Low

A company seeking to enter the market should focus on manufacturing cost, reliable supply, a complete strength portfolio, and regulatory execution rather than relying on broad patent protection.

What is the revenue exposure for fenofibrate manufacturers?

Fenofibrate is most valuable to manufacturers with an established generic platform. As a standalone product, it is unlikely to support premium pricing. Revenue quality depends on volume, supply reliability, and portfolio placement.

Revenue scenarios for a generic supplier

Supplier position	Annual net sales potential	Commercial profile
Small regional supplier	$1 million to $10 million	Limited strengths or local distribution
Established multi-country generic supplier	$10 million to $50 million	Several strengths and stable contracts
Large portfolio supplier	$50 million to $150 million	Broad geographic coverage and channel access
Branded differentiated product	Variable, generally declining	Requires formulation, adherence, or combination value

These ranges are indicative product-level scenarios, not audited company forecasts. The most attractive opportunity is usually portfolio aggregation, where fenofibrate supports a broader cardiovascular or diabetes franchise.

What generic launch scenarios are likely?

Base-case scenario

Generic suppliers maintain current availability, prices decline gradually, and prescription volume remains stable. US sales fall about 2% to 4% annually. Global sales decline more slowly because emerging-market volume partly offsets developed-market price erosion.

Downside scenario

Several additional suppliers enter, a major payer changes its preferred generic supplier, or an established manufacturer resumes full capacity. US prices fall sharply, with molecule sales declining 6% to 9% annually.

Upside scenario

Demand increases in severe hypertriglyceridemia, emerging markets expand access, or a differentiated formulation secures reimbursement. Global revenue is broadly stable, but a conventional generic product still has limited pricing power.

What licensing deals affect fenofibrate?

Fenofibrate has had historical commercial licensing, co-promotion, and distribution arrangements around products such as Tricor and related formulations. The principal licensing value was tied to branded formulation rights, regulatory approvals, and geographic commercialization.

The current generic market is more likely to use:

• Contract manufacturing agreements.
• API supply agreements.
• Distribution partnerships.
• Private-label arrangements.
• Authorized-generic supply contracts.
• Regional marketing rights.

New licensing value would be strongest for a combination product, modified-release formulation, or product with evidence supporting a defined high-risk population. A license covering conventional immediate-release fenofibrate would have limited negotiating power because multiple generic alternatives are available.

What litigation and settlement issues affect fenofibrate?

The historical litigation pattern involved originator patents covering branded formulations and generic companies seeking earlier market entry through Paragraph IV certifications. Those disputes were commercially important before the market became broadly generic.

The current litigation risk is lower at the molecule level. Potential disputes could still involve:

• Formulation patents.
• Patent listing disputes.
• ANDA infringement allegations.
• Manufacturing-process claims.
• Trade dress and trademark issues.
• Product liability and labeling claims.
• Antitrust allegations related to generic contracting.

Settlement agreements would have limited present market impact unless they concern a newly patented formulation with meaningful clinical or commercial differentiation.

How does fenofibrate compare with fenofibric acid products?

Fenofibric acid products were developed partly to offer a different active moiety and formulation strategy. Trilipix was positioned for use alone or with statins in mixed dyslipidemia.

Fenofibric acid may have formulation and dosing distinctions, but the products compete for a similar clinical population. The commercial advantage is limited when payers and prescribers can substitute lower-cost fenofibrate products. The key diligence question is whether a specific product has automatic substitution, preferred formulary status, or a clinically meaningful dosing advantage.

Key Takeaways

• Fenofibrate is a mature generic small molecule with expired core compound protection.
• Generic competition is the dominant commercial force.
• The base-case global market is modeled at approximately $1.10 billion in 2024, declining to about $930 million by 2029.
• The US market is modeled at approximately $300 million in 2024, declining to about $259 million by 2029.
• Severe hypertriglyceridemia remains the most durable demand segment.
• Routine cardiovascular prevention is a weak growth driver because clinical-outcomes evidence for broad statin combination use is limited.
• Biosimilar risk does not apply.
• Paragraph IV risk is historically important but currently secondary to generic price and supply competition.
• Formulation patents created the main historical barrier, but broad formulation protection has largely expired or been commercially overcome.
• The best commercial strategy is portfolio-based generic supply, not premium pricing for conventional fenofibrate.
• New product value would require differentiated delivery, combination therapy, or a defined clinical benefit.

FAQs About Fenofibrate Market Size and Commercial Outlook

Is fenofibrate still a profitable generic drug?

Yes, but profitability depends on manufacturing scale, contract access, and supply reliability. Conventional fenofibrate generally has low unit margins and limited pricing power.

Does fenofibrate have patent protection in the United States?

The original compound patent and primary exclusivity periods have expired. Narrow formulation or process patents may exist for specific products, but they do not create broad protection for conventional fenofibrate.

Is fenofibrate subject to biosimilar competition?

No. Fenofibrate is a small-molecule drug regulated through the generic ANDA pathway, not the biosimilar pathway.

What drug most directly competes with fenofibrate?

Prescription omega-3 products and other triglyceride-lowering therapies are the closest pharmacologic competitors. Statins are the primary broader lipid-management competitor but mainly target LDL cholesterol.

Will fenofibrate sales increase through 2030?

A sustained global increase is unlikely in the base case. Volume may remain stable or rise in emerging markets, but generic price erosion in the United States and Europe is expected to produce flat-to-declining total revenue.

References

1. U.S. Food and Drug Administration. (2023). Fenofibrate tablets prescribing information. FDA-approved labeling.

2. ACCORD Study Group. (2010). Effects of combination lipid therapy in type 2 diabetes mellitus. New England Journal of Medicine, 362(17), 1563-1574.

3. Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082-e1143.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. American College of Cardiology. (2021). Expert consensus decision pathway on the management of persistent hypertriglyceridemia. Journal of the American College of Cardiology, 78(9), 960-993.